ID   SNU-2535LR
AC   CVCL_C5TR
DR   Wikidata; Q116050519
RX   PubMed=35852680;
CC   Population: Korean.
CC   Characteristics: Resistant to crizotinib (from parent cell line).
CC   Characteristics: Has lost the ALK p.Gly1269Ala mutation of the parent cell line (PubMed=35852680).
CC   Selected for resistance to: ChEBI; CHEBI_143117; Lorlatinib (Lorbrena; Lorviqua; PF-6463922).
CC   Sequence variation: Gene fusion; HGNC; HGNC:427; ALK + HGNC; HGNC:1316; EML4; Name(s)=EML4-ALK (PubMed=35852680).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Glu285Val (c.854A>T); ClinVar=VCV000012384; Zygosity=Homozygous (PubMed=35852680).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_R756 ! SNU-2535
SX   Female
AG   57Y
CA   Cancer cell line
DT   Created: 15-12-22; Last updated: 19-12-24; Version: 4
//
RX   PubMed=35852680; DOI=10.1007/s12094-022-02884-x;
RA   Xie B., Qiu Y., Zhou J., Du D., Ma H.-C., Ji J.-P., Zhu L.-Q.,
RA   Zhang W.-M.;
RT   "Establishment of an acquired lorlatinib-resistant cell line of
RT   non-small cell lung cancer and its mediated resistance mechanism.";
RL   Clin. Transl. Oncol. 24:2231-2240(2022).
//